Tonix director granted options on 22,700 shares

Tonix Pharmaceuticals Holding Corp. director Margaret Smith Bell received a grant of stock options as part of equity compensation.

Rhea-AI Filing Summary

Tonix Pharmaceuticals Holding Corp. director Margaret Smith Bell received a grant of stock options as part of equity compensation. She was awarded options covering 22,700 shares of common stock at an exercise price of $13.28 per share. The options were granted under the company’s 2026 Stock Incentive Plan and will vest on the earlier of the one-year anniversary of the grant date or the company’s 2027 Annual Meeting of Stockholders. Following this award, she holds derivative rights to 22,700 shares through these options, which expire in 2036.

Insider Trade Summary

Grant/Award: 22,700 shares

Grant/Award 1 txn

Insider Bell Margaret Smith

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	22,700	$0.00	$0.00

Holdings After Transaction: Stock Option — 22,700 contracts (Direct)

Footnotes (1)

1. F1. The option was granted pursuant to the Issuer's 2026 Stock Incentive Plan and vests on the earlier of the one year anniversary of the grant date and the Issuer's 2027 Annual Meeting of Stockholders.

Key Figures

Option grant size: 22,700 shares Exercise price: $13.28 per share Post-grant derivative holdings: 22,700 options +1 more

4 metrics

Option grant size 22,700 shares Stock options on common stock granted to director

Exercise price $13.28 per share Conversion or exercise price of stock options

Post-grant derivative holdings 22,700 options Total options held following this transaction

Option expiration date May 12, 2036 Expiration of granted stock options

Key Terms

Stock Option, 2026 Stock Incentive Plan, Annual Meeting of Stockholders, exercise price

4 terms

Stock Option financial

"security_title: Stock Option"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

2026 Stock Incentive Plan financial

"The option was granted pursuant to the Issuer's 2026 Stock Incentive Plan"

Annual Meeting of Stockholders financial

"vests on the earlier of the one year anniversary of the grant date and the Issuer's 2027 Annual Meeting of Stockholders"

exercise price financial

"conversion_or_exercise_price: 13.2800"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Tonix Pharmaceuticals (TNXP) report for Margaret Smith Bell?

Tonix Pharmaceuticals reported a stock option grant to director Margaret Smith Bell. She received options on 22,700 shares of common stock as equity compensation, with specific vesting terms tied to time and the 2027 Annual Meeting of Stockholders.

How many Tonix Pharmaceuticals (TNXP) shares are covered by the new stock options?

The new stock option grant covers 22,700 shares of Tonix common stock. These options give the director the right to purchase that number of shares at a fixed exercise price once vesting conditions are met.

What is the exercise price of the Tonix Pharmaceuticals (TNXP) options granted?

The options have an exercise price of $13.28 per share. This means the director can buy Tonix common stock at $13.28 per share upon vesting and exercise, regardless of the market price at that time.

When do the newly granted Tonix Pharmaceuticals (TNXP) options vest?

The options vest on the earlier of two events. They vest on the one-year anniversary of the grant date or on the date of Tonix’s 2027 Annual Meeting of Stockholders, whichever occurs first, according to the grant footnote.

When do Margaret Smith Bell’s Tonix Pharmaceuticals (TNXP) options expire?

The granted stock options expire on May 12, 2036. After that expiration date, the director can no longer exercise these options to purchase Tonix common shares, even if they were previously vested and unexercised.

Under which plan were the Tonix Pharmaceuticals (TNXP) options granted?

The options were granted under Tonix’s 2026 Stock Incentive Plan. This plan governs equity awards such as stock options for eligible participants, including directors, and sets the terms for vesting, exercise, and expiration.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/14/2026 - 05:47 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bell Margaret Smith

(Last) (First) (Middle)

C/O TONIX PHARMACEUTICALS HOLDING CORP.

200 CONNELL DRIVE, SUITE 3100

(Street)

BERKELEY HEIGHTS NEW JERSEY 07922

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tonix Pharmaceuticals Holding Corp. [ TNXP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$13.28	05/12/2026		A		22,700		05/12/2027(1)	05/12/2036	Common Stock	22,700	$0.00(1)	22,700	D

Explanation of Responses:

1. The option was granted pursuant to the Issuer's 2026 Stock Incentive Plan and vests on the earlier of the one year anniversary of the grant date and the Issuer's 2027 Annual Meeting of Stockholders.

	/s/ Jessica Morris, Attorney-in-Fact	05/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)